First-in-disease use of kyverna therapeutics' kyv-101 in patients with progressive multiple sclerosis published in med

Two patients were treated with kyv-101, a fully human anti-cd19 car t-cell product candidate, in germany as part of a named patient program after failure to respond to conventional therapies the treatment resulted in an acceptable safety profile, with no observed clinical signs of early neurotoxicity, warranting larger clinical studies in subjects with multiple sclerosis emeryville, calif. , march 29, 2024 /prnewswire/ -- kyverna therapeutics, inc. (kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, announces today the publication in med1, of a report describing the first use of kyv-101, a fully human anti-cd19 chimeric antigen receptor (car) t-cell product candidate, in two patients suffering from progressive multiple sclerosis (ms) as part of a named patient program for critically ill patients after both patients failed to respond to conventional therapies.
KYTX Ratings Summary
KYTX Quant Ranking